Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US
Click here to find out more how the Boehringer Ingelheim veterinary scholars program has helped 3,500 people over 30 years. Read five of their stories here.
: A biosimilar is a version of a biologic medication that is made by a different company than the one that invented it, with no clinically meaningful differences in terms of safety, potency and purity.
Learn more about the experiences of living with nonsmall cell lung cancer and cholangiocarcinoma as well as caring for a loved one during a cancer journey.
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US
Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.
Disability Inclusion at Work: Top Score | Boehringer Ingelheim US
Click here to read more on Boehringer Ingelheim receiving a 100 score with Disability:IN’s “Best Place to Work for Disability Inclusion” for the 5th year!